Epygen Biotech

02/11/2021

The need for biopharma execs to effectively engage CROs in decentralized clinical trials will only increase in the years to come. This article examines the results of a recent Ernst & Young (EY) study and also offers some recommendations for sponsors and CROs to be...

28/10/2021

Single Booster can do the trick
https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-021-02090-6

Background Coronavirus SARS-CoV-2, the causative agent of COVID-19, has caused a still evolving global pandemic. Given the worldwide vaccination campaign, the understanding of the vaccine-induced versus COVID-19-induced immunity will contribute to adjusting vaccine dosing strategies and speeding-up....

11/01/2021

24/12/2020

GenoCoV Multiplex RT-PCR would be able to detect the new COVID-19 N501Y Variant
More reading: https://www.who.int/csr/don/21-december-2020-sars-cov2-variant-united-kingdom/en/

24/10/2020

A throwback to our Free health camp for hundreds of people on this auspicious day since the last three years.

17/10/2020

https://www.imapac.com/en/this-weeks-vaccine-news-roundup-8/

Siam Bioscience signs agreement with AstraZeneca to produce and supply potential COVID-19 vaccine for Thailand

17/10/2020

https://www.businessinsider.in/india/news/india-covid-19-vaccine-tracker-sii-requests-dcgi-to-alter-clinical-norms-epygen-biotech-enters-vaccine-race/articleshow/78673313.cms

There are about 42 vaccines under clinical evaluation around the world — of which three are from India. Epygen Biotech has joined Bharat Biotech, Serum Institute

17/10/2020

https://www.zacnetwork.org/another-indian-firm-joins-race-for-covid-vaccine/

Epygen Biotech, a biopharma company with operations in Mumbai and Dubai, has tied up with US-based biotech firm Dyadic to work on a potential Covid-19 vaccine, reports Rupali Mukherjee. ...

15/10/2020

Coronavirus vaccine update: Biopharma company Epygen Biotech with operations in Mumbai and Dubai is planning to launch an affordable COVID-19 vaccine with an aim to roll out 500 million doses within six months

15/10/2020

To conduct clinical trials in India using Dyadic's C1 expressed RBD antigen of the SARS-CoV-2 Spike Protein

15/10/2020

Mumbai: Epygen Biotech, a biopharma company with operations in Mumbai and Dubai, has tied up with US-based biotech firm Dyadic to work on a potential .

13/10/2020

Dyadic (Nasdaq DYAI) talks about Epygen tie up before US markets open after long weekend! Epygen can make 500 million vaccines within 10 months.

* C1 Expression of SARS-CoV-2 Monoclonal Antibody Achieved * Ten On-going Animal Trials of C1 Expressed SARS-CoV-2 Receptor Binding Domain (RBD) Antigen by Seven Different Collaborators * Record Expression Level of C1 SARS-CoV-2 RBD Antigen (3 g/l in 5 days) * Non-Exclusive Technology Usage Agreemen...